OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
Bojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
The Journal of Clinical Pharmacology (2020) Vol. 60, Iss. 12, pp. 1642-1654
Open Access | Times Cited: 18
Bojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
The Journal of Clinical Pharmacology (2020) Vol. 60, Iss. 12, pp. 1642-1654
Open Access | Times Cited: 18
Showing 18 citing articles:
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Lemborexant
Kristian Beran, Bertil Abrahamsson, Naseem A. Charoo, et al.
Journal of Pharmaceutical Sciences (2024)
Closed Access | Times Cited: 2
Kristian Beran, Bertil Abrahamsson, Naseem A. Charoo, et al.
Journal of Pharmaceutical Sciences (2024)
Closed Access | Times Cited: 2
Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
Ishani Landry, Jagadeesh Aluri, Kenya Nakai, et al.
Clinical Pharmacology in Drug Development (2021) Vol. 10, Iss. 6, pp. 681-690
Open Access | Times Cited: 16
Ishani Landry, Jagadeesh Aluri, Kenya Nakai, et al.
Clinical Pharmacology in Drug Development (2021) Vol. 10, Iss. 6, pp. 681-690
Open Access | Times Cited: 16
Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
Amitabh Dash, Kate Pinner, Yuichi Inoue, et al.
Sleep Medicine X (2022) Vol. 4, pp. 100044-100044
Open Access | Times Cited: 9
Amitabh Dash, Kate Pinner, Yuichi Inoue, et al.
Sleep Medicine X (2022) Vol. 4, pp. 100044-100044
Open Access | Times Cited: 9
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
Andreas Krause, Dominik Lott, Janneke M. Brussee, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 12, Iss. 1, pp. 74-86
Open Access | Times Cited: 8
Andreas Krause, Dominik Lott, Janneke M. Brussee, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 12, Iss. 1, pp. 74-86
Open Access | Times Cited: 8
Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
Takashi Ueno, Yukiko Miyajima, Ishani Landry, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 10, Iss. 5, pp. 455-466
Open Access | Times Cited: 10
Takashi Ueno, Yukiko Miyajima, Ishani Landry, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 10, Iss. 5, pp. 455-466
Open Access | Times Cited: 10
Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents
Shunya Ikeda, Mie Azuma, Kenichi Fujimoto, et al.
Psychological Medicine (2022) Vol. 52, Iss. 13, pp. 2822-2834
Open Access | Times Cited: 7
Shunya Ikeda, Mie Azuma, Kenichi Fujimoto, et al.
Psychological Medicine (2022) Vol. 52, Iss. 13, pp. 2822-2834
Open Access | Times Cited: 7
Evaluating lemborexant for the treatment of insomnia
Gary Zammit, Andrew D. Krystal
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1235-1243
Closed Access | Times Cited: 7
Gary Zammit, Andrew D. Krystal
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1235-1243
Closed Access | Times Cited: 7
Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study
Yuichi Inoue, Takeshi Watanabe, Shuya Takashima, et al.
Journal of Clinical Sleep Medicine (2021) Vol. 17, Iss. 5, pp. 1067-1074
Open Access | Times Cited: 6
Yuichi Inoue, Takeshi Watanabe, Shuya Takashima, et al.
Journal of Clinical Sleep Medicine (2021) Vol. 17, Iss. 5, pp. 1067-1074
Open Access | Times Cited: 6
Lemborexant levels in maternal serum, cord blood, and breast milk during pregnancy and lactation: A case report
Jumpei Saito, Mariko Ishii, Noriko Sandaiji, et al.
Psychiatry and Clinical Neurosciences Reports (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 2
Jumpei Saito, Mariko Ishii, Noriko Sandaiji, et al.
Psychiatry and Clinical Neurosciences Reports (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 2
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
Ishani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives (2021) Vol. 9, Iss. 2
Open Access | Times Cited: 5
Ishani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives (2021) Vol. 9, Iss. 2
Open Access | Times Cited: 5
Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
Bojan Lalovic, Ishani Landry, Margaret Moline, et al.
The Journal of Clinical Pharmacology (2022) Vol. 63, Iss. 4, pp. 498-511
Closed Access | Times Cited: 1
Bojan Lalovic, Ishani Landry, Margaret Moline, et al.
The Journal of Clinical Pharmacology (2022) Vol. 63, Iss. 4, pp. 498-511
Closed Access | Times Cited: 1
